India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg.
The FDA approved Lupin's Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga for the indications in the approved labelling.
Farxiga, a brand of biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN), is indicated for the treatment of type 2 diabetes, chronic kidney disease, and symptomatic chronic heart failure.
FDA approves MEKanistic Therapeutics' IND for MTX-531
Matter Bio submits first IND application for Lm-LLO-TT
Hansa Biopharma signs EUR115m IDEFIRIX licensing deal with SERB
Lupin receives tentative FDA approval for Revefenacin Inhalation Solution
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
Akeso reports results from Phase II trial of ligufalimab combination therapy in AML
US FDA approves Datar Cancer Genetics' comprehensive genomic profiling assay for solid tumours